Proteinopathy, oxidative stress and mitochondrial dysfunction: Cross talk in alzheimer’s disease and parkinson’s disease

Drug Design, Development and Therapy

Volumn 11, Issue , 2017, Pages 797-810

  Ganguly, Gargi ^a   Chakrabarti, Sasanka ^b   Chatterjee, Uttara ^a   Saso, Luciano ^c  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b ICAREInstitute of Medical Sciences and Research ^*  (India)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Amyloid beta; Mitochondrial dysfunction; Oxidative stress; Proteinopathy; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; CELL PROTEIN; CYCLIN DEPENDENT KINASE 5; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; METAL ION; OLIGOMER; OXYGEN RADICAL; PARKIN; PINK1 PROTEIN; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; UNCLASSIFIED DRUG; PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BIOACCUMULATION; COGNITIVE DEFECT; CORPUS STRIATUM; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE MUTATION; HUMAN; LEWY BODY; MITOPHAGY; MORBIDITY; MORTALITY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEINOPATHY; METABOLISM; MITOCHONDRION; PATHOLOGY;

ALZHEIMER DISEASE; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEINS;

EID: 85015976566     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S130514     Document Type: Article

References (151)

1. Davie CA. A review of Parkinson’s disease. Br Med Bull. 2008;86(1):109-127.
2. Chakrabarti S, Khemka VK, Banerjee A, Chatterjee G, Ganguly A, Biswas A. Metabolic risk factors of sporadic Alzheimer’s disease: implications in the pathology, pathogenesis and treatment. Aging Dis. 2015;6(4):282-299.
3. Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003;348(14):1356-1364.
4. Xie A, Gao J, Xu L, Meng D. Shared mechanisms of neurodegeneration in Alzheimer’s disease and Parkinson’s disease. Biomed Res Int. 2014;2014:648740.
5. Perier C, Vila M. Mitochondrial biology and Parkinson’s disease. Cold Spring Harb Perspect Med. 2011;2(2):a009332.
6. Bonda DJ, Smith MA, Perry G, Lee HG, Wang X, Zhu X. The mito­chondrial dynamics of Alzheimer’s disease and Parkinson’s disease offer important opportunities for therapeutic intervention. Curr Pharm Des. 2011;17(31):3374-3380.
7. Subramaniam SR, Chesselet M-F. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol. 2013;106-107:17-32.
8. Xie W, Wan OW, Chung KK. New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson’s disease. Biochim Biophys Acta. 2010;1802(11):935-941.
9. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med. 2002;32(11):1050-1060.
10. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med. 2008;14(2):45-53.
11. Cookson MR. α-Synuclein and neuronal cell death. Mol Neurodegener. 2009;4:9.
12. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.
13. Friedrich RP, Tepper K, Ronicke R, et al. Mechanism of amyloid plaque formation suggests an intracellular basis of a pathogenicity. Proc Natl Acad Sci U S A. 2010;107(5):1942-1947.
14. Uversky VN, Eliezer D. Biophysics of Parkinson’s Disease: structure and aggregation of α-synuclein. Curr Protein Peptide Sci. 2009;10:483-499.
15. Kovacs GG, Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol. 2010;29(5):271-288.
16. O’brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Ann Rev Neurosci. 2011;34:185-204.
17. Cahill CM, Lahiri DK, Huang X, Rogers JT. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta. 2009;1790(7):615-628.
18. Jowaed A, Schmitt I, Kaut O, Wüllner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains. J Neurosci. 2010;30(18):6355-6359.
19. Takalo M, Salminen A, Soininen H, Hiltunen M, Haapasalo A. Protein aggregation and degradation mechanisms in neurodegenerative diseases. Am J Neurodegener Dis. 2013;2(1):1-14.
20. Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med. 2015;47:e147.
21. Morimoto RI. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 2008;22(11):1427-1438.
22. Niforou K, Cheimonidou C, Trougakos IP. Molecular chaperones and proteostasis regulation during redox imbalance. Redox Biol. 2014;2:323-332.
23. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 1996;10(7):709-720.
24. Aiken CT, Kaake RM, Wang X, Huang L. Oxidative stress-mediated regulation of proteasome complexes. Mol Cell Proteomics. 2011;10(5):R110006924.
25. Pajares M, Jiménez-moreno N, Dias IH, et al. Redox control of protein degradation. Redox Biol. 2015;6:409-420.
26. Xiang W, Menges S, Schlachetzki J, et al. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity. Mol Neurodegener. 2015;10:8.
27. Snead D, Eliezer D. Alpha-synuclein function and dysfunction on cel­lular membranes. Exp Neurobiol. 2014;23(4):292-313.
28. Banerjee K, Sinha M, Pham Cle L, et al. Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson’s disease. FEBS Lett. 2010;584(8):1571-1576.
29. Wang X, Su B, Lee H, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci. 2009;29(28):9090-9103.
30. Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J Neurosci. 2006;26(35):9057-9068.
31. Protter D, Lang C, Cooper AA. α-Synuclein and mitochondrial dysfunction: a pathogenic partnership in Parkinson’s disease. Parkinson’s Dis. 2012;2012.
32. Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener. 2012;1(1):18.
33. Armstrong RA. The pathogenesis of Alzheimer’s disease: a reevaluation of the Amyloid cascade Hypothesis. Int J Alzheimers Dis. 2011;2011:1-6.
34. Jiang S, Li Y, Zhang X, Bu G, Xu H, Zhang Y. Trafficking regulation of proteins in Alzheimer’s disease. Mol Neurodegener. 2014;9:6.
35. Mondragón-rodríguez S, Perry G, Zhu X, Moreira PI, Acevedo-aquino MC, Williams S. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer’s disease. Oxid Med Cell Longev. 2013;2013:940603.
36. Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med. 1996;2(7):783-787.
37. Butterfield DA, Swomley AM, Sultana S. Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal. 2013;19:823-835.
38. Butterfield DA, Di Domenico F, Swomley AM, Head E, Perluigi M. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in down’s syndrome and Alzheimer’s disease brain. Biochem J. 2014;463(2):177-189.
39. Theuns J, Van Broeckhoven C. Transcriptional regulation of Alzheimer’s disease genes: implications for susceptibility. Hum Mol Genet. 2000;9(16):2383-2394.
40. Hoffman PW, Chernak JM. DNA binding and regulatory effects of transcription factors SP1 and USF at the rat amyloid precursor protein gene promoter. Nucleic Acids Res. 1995;23(12):2229-2235.
41. Picone P, Nuzzo D, Caruana L, et al. Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-κB activation: use of insulin to attenuate metformin’s effect. Biochim Biophys Acta. 2015;1853(5):1046-1059.
42. Ko SY, Lin YP, Lin YS, Chang SS. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med. 2010;49(3):474-480.
43. Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem. 2002;277(47):45518-45528.
44. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT. Redox-active metals, oxidative stress, and Alzheimer’s disease pathology. Ann N Y Acad Sci. 2004;1012:153-163.
45. Chen XF, Zhang YW, Xu H, Bu G. Transcriptional regulation and its misregulation in Alzheimer’s disease. Mol Brain. 2013;6:44.
46. Chami L, Checler F. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer’s disease. Mol Neurodegener. 2012;7:52.
47. Guglielmotto M, Aragno M, Autelli R, et al. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem. 2009;108(4):1045-1056.
48. Kaur U, Banerjee P, Bir A, Sinha M, Biswas A, Chakrabarti S. Reactive oxygen species, redox signaling and neuroinflammation in Alzheimer’s disease: the NF-κB connection. Curr Top Med Chem. 2015;15(5):446-457.
49. Tong Y, Zhou W, Fung V, et al. Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm. 2004;112(3):455-469.
50. Tamagno E, Bardini P, Obbili A, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis. 2002;10(3):279-288.
51. Tamagno E, Parola M, Bardini P, et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem. 2005;92(3):628-636.
52. Tamagno E, Guglielmotto M, Aragno M, et al. Oxidative stress activates a positive feedback between the γ- and β-secretase cleavages of the β-amyloid precursor protein. J Neurochem. 2008;104(3):683-695.
53. Mouton-liger F, Paquet C, Dumurgier J, et al. Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2α pathway. Biochem Biophys Acta. 2012;1822(6):885-896.
54. Misonou H, Morishima-kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry. 2000;39(23):6951-6959.
55. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2009;8(1):16-30.
56. Bates KA, Verdile G, Li Q-X, et al. Clearance mechanisms of Alzheimer’s amyloid-β peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatr. 2008;14(5):469-486.
57. Ramanathan A, Nelson AR, Sagare AP, Zlokovic BV. Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer’s disease: the role, regulation and restoration of LRP1. Front Aging Neurosci. 2015;7:136.
58. Kadowaki H, Nishitoh H, Urano F, et al. Amyloid β induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ. 2005;12(1):19-24.
59. Behl C. Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 1994;77(6):817-827.
60. Chakrabarti S, Sinha M, Thakurta IG, Banerjee P, Chattopadhyay M. Oxidative stress and amyloid beta toxicity in Alzheimer’s disease: intervention in a complex relationship by antioxidants. Curr Med Chem. 2013;20(37):4648-4664.
61. Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer’s disease amyloid β peptide. Biochim Biophys Acta. 2007;1768(8):1976-1990.
62. Sinha M, Bhowmick P, Banerjee A, Chakrabarti S. Antioxidant role of amyloid β protein in cell-free and biological systems: implication for the pathogenesis of Alzheimer disease. Free Radic Biol Med. 2013;56:184-192.
63. Shelat PB, Chalimoniuk M, Wang JH, et al. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem. 2008;106(1):45-55.
64. Hu H, Li M. Mitochondria-targeted antioxidant mitotempo protects mitochondrial function against amyloid beta toxicity in primary cultured mouse neurons. Biochem Biophys Res Commun. 2016;478(1):174-180.
65. Qin L, Liu Y, Cooper C, Liu B, Wilson B, Hong J-S. Microglia enhance β-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem. 2002;83(4):973-983.
66. Qin B, Cartier L, Dubois-dauphin M, Li B, Serrander L, Krause KH. A key role for the microglial NADPH oxidase in APP-dependent killing of neurons. Neurobiol Aging. 2006;27(11):1577-1587.
67. Doens D, Fernández PL. Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis. J Neuroinflammation. 2014;11:48.
68. Coraci IS, Husemann J, Berman JW, et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer’s disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol. 2002;160(1):101-112.
69. Zhang D, Hu X, Qian L, et al. Microglial MAC1 receptor and PI3K are essential in mediating β-amyloid peptide-induced microglial activation and subsequent neurotoxicity. J Neuroinflammation. 2011;8(1):3.
70. Mondragón-rodríguez S, Perry G, Luna-muñoz J, Acevedo-aquino MC, Williams S. Phosphorylation of tau protein at sites Ser (396-404) is one of the earliest events in Alzheimer’s disease and Down syndrome. Neuropathol Appl Neurobiol. 2014;40(2):121-135.
71. Alavi Naini SM, Soussi-yanicostas N. Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies? Oxid Med Cell Longev. 2015;2015:151979.
72. Su B, Wang X, Lee HG, et al. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci Lett. 2010;468(3):267-271.
73. Giraldo E, Lloret A, Fuchsberger T, Viña J. Aβ and tau toxicities in Alzheimer’s are linked via oxidative stress-induced p38 activation: protective role of vitamin E. Redox Biol. 2014;2:873-877.
74. Lovell MA, Xiong S, Xie C, Davies P, Markesbery WR. Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis. 2004;6(6):659-671.
75. Egaña JT, Zambrano C, Nuñez MT, Gonzalez-billault C, Maccioni RB. Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures. Biometals. 2003;16(1):215-223.
76. Zambrano CA, Egaña JT, Núñez MT, Maccioni RB, González-billault C. Oxidative stress promotes tau dephosphorylation in neuronal cells: the roles of cdk5 and PP1. Free Radic Biol Med. 2004;36(11):1393-1402.
77. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta. 2010;1802(1):2-10.
78. Onyango IG, Dennis J, Khan SM. Mitochondrial dysfunction in Alzheimer’s disease and the rationale for bioenergetics based therapies. Aging Dis. 2016;7(2):201-214.
79. Chen JX, Yan SD. Amyloid-beta-induced mitochondrial dysfunction. J Alzheimers Dis. 2007;12(2):177-184.
80. Mossmann D, Vögtle F, Taskin AA, et al. Amyloid-β peptide induces mitochondrial dysfunction by inhibition of preprotein maturation. Cell Metab. 2014;20(4):662-669.
81. Spuch C, Ortolano S, Navarro C. New insights in the amyloid-beta interaction with mitochondria. J Aging Res. 2012;2012:324968.
82. Sinha M, Behera P, Bhowmick P, Banerjee K, Basu S, Chakrabarti S. Aging promotes amyloid-β peptide induced mitochondrial dysfunctions in rat brain: a molecular link between aging and Alzheimer’s disease. J Alzheimers Dis. 2011;27(4):753-765.
83. Arispe N, Diaz JC, Simakova O. Abeta ion channels. Prospects for treating Alzheimer’s disease with Abeta channel blockers. Biochim Biophys Acta. 2007;1768(8):1952-1965.
84. Lal R, Lin H, Quist AP. Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim Biophys Acta. 2007;1768(8):1966-1975.
85. Zhu D, Lai Y, Shelat PB, Hu C, Sun GY, Lee JC. Phospholipases A2 mediate amyloid-beta peptide-induced mitochondrial dysfunction. J Neurosci. 2006;26(43):11111-11119.
86. Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci. 2004;24(2):565-575.
87. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583-1590.
88. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(1):a008888.
89. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318(1):121-134.
90. Stefanis L. Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. 2011;2:a009399.
91. Roostaee A, Beaudoin S, Staskevicius A, Roucou X. Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization. Mol Neurodegener. 2013;8:5.
92. Matsumoto L, Takuma H, Tamaoka A, et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson’s disease. PLoS One. 2010;5(11):e15522.
93. Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-ramos M. α-Synuclein expression is modulated at the translational level by iron. Neuroreport. 2012;23(9):576-580.
94. Dehay B, Martinez-vicente M, Caldwell GA, et al. Lysosomal impair­ment in Parkinson’s disease. Mov Disord. 2013;28(6):725-732.
95. Cook C, Petrucelli L. A critical evaluation of the ubiquitin-proteasome system in Parkinson’s disease. Biochim Biophys Acta. 2009;1792(7):664-675.
96. Mcnaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol. 2003;179(1):38-46.
97. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev. 2001;21(4):245-273.
98. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat Rev Neurosci. 2001;2(8):589-594.
99. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol. 2004;56(1):149-162.
100. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol. 2005;62(3):353-357.
101. Tanaka Y, Engelender S, Igarashi S, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet. 2001;10(9):919-926.
102. Perez-Alvarez S, Solesio ME, Manzanares J, Jordán J, Galindo MF. Lactacystin requires reactive oxygen species and BAX redistribution to induce mitochondria mediated cell death. Br J Pharmacol. 2009;158(4):1121-1130.
103. Zhou ZD, Lim TM. Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. Free Radic Res. 2009;43(4):417-430.
104. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6’ proteasomal protein and inhibit proteasomal function. J Biol Chem. 2003;278(14):11753-11759.
105. Simón-sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet. 2009;41(12):1308-1312.
106. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2002;99(16):10813-10818.
107. Oliveras-salvá M, Van der Perren A, Casadei N, et al. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol Neurodegener. 2013;8:44.
108. Paumier KL, Luk KC, Manfredsson FP, et al. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis. 2015;82:185-199.
109. Recasens A, Dehay B, Bové J, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014;75(3):351-362.
110. Bisaglia M, Greggio E, Maric D, Miller DW, Cookson MR, Bubacco L. Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci. 2010;11:41.
111. Mullin S, Schapira A. A-synuclein and mitochondrial dysfunction in Parkinson’s disease. Mol Neurobiol. 2013;47(2):587-597.
112. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem. 1990;54(3):823-827.
113. Blake CI, Spitz E, Leehey M, Hoffer BJ, Boyson SJ. Platelet mitochon­drial respiratory chain function in Parkinson’s disease. Mov Disord. 1997;12(1):3-8.
114. Blin O, Desnuelle C, Rascol O, et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson’s disease and multiple system atrophy. J Neurol Sci. 1994;125(1):95-101.
115. Santos D, Esteves AR, Silva DF, Januário C, Cardoso SM. The impact of mitochondrial fusion and fission modulation in sporadic Parkinson’s disease. Mol Neurobiol. 2015;52(1):573-586.
116. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson’s disease. Ann Neurol. 1996;40(4):663-671.
117. Trimmer PA, Bennett JP. The cybrid model of sporadic Parkinson’s disease. Exp Neurol. 2009;218(2):320-325.
118. Dauer W, Przedborski S. Parkinson’s disease. Neuron. 2003;39(6):889-909.
119. Iglesias-gonzález J, Sánchez-iglesias S, Méndez-Álvarez E, et al. Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase. Neurochem Res. 2012;37(10):2150-2160.
120. Winklhofer KF, Haass C. Mitochondrial dysfunction in Parkinson’s disease. Biochim Biophys Acta. 2010;1802(1):29-44.
121. Jana S, Sinha M, Chanda D, et al. Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson’s disease. Biochim Biophys Acta. 2011;1812(6):663-673.
122. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 2006;38(5):515-517.
123. Deas E, Wood NW, Plun-favreau H. Mitophagy and Parkinson’s disease: the PINK1-parkin link. Biochim Biophys Acta. 2011;1813(4):623-633.
124. Ding WX, Yin XM. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem. 2012;393(7):547-564.
125. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron. 2015;85(2):257-273.
126. Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate parkin. PLoS Biol. 2010;8(1):e1000298.
127. Vives-Bauza C, Zhou C, Huang Y, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A. 2010;107(1):378-383.
128. Matsuda N, Sato S, Shiba K, et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol. 2010;189(2):211-221.
129. Lee S, Zhang C, Liu X. Role of glucose metabolism and ATP in maintaining PINK1 levels during Parkin-mediated mitochondrial damage responses. J Biol Chem. 2015;290(2):904-917.
130. Van Laar VS, Arnold B, Cassady SJ, Chu CT, Burton EA, Berman SB. Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization. Hum Mol Genet. 2011;20(5):927-940.
131. Norris KL, Hao R, Chen LF, et al. Convergence of Parkin, PINK1, and α-synuclein on stress-induced mitochondrial morphological remodeling. J Biol Chem. 2015;290(22):13862-13874.
132. Liu W, Vives-Bauza C, Acín-Peréz R, et al. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson’s disease. PLoS One. 2009;4(2):e4597.
133. Devi L, Anandatheerthavarada HK. Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer’s and Parkinson’s diseases. Biochim Biophys Acta. 2010;1802(1):11-19.
134. Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett. 2010;486(3):235-239.
135. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett. 1998;251(3):205-208.
136. Dikiy I, Eliezer D. Folding and misfolding of alpha-synuclein on membranes. Biochim Biophys Acta. 2012;1818(4):1013-1018.
137. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14(1):38-48.
138. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008;283(14):9089-9100.
139. Reeve AK, Ludtmann MH, Angelova PR, et al. Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons. Cell Death Dis. 2015;6:e1820.
140. Bir A, Sen O, Anand S, et al. α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson’s disease. J Neurochem. 2014;131(6):868-877.
141. Kamp F, Exner N, Lutz AK, et al. Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 2010;29(20):3571-3589.
142. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology. 1996;47(6 suppl 3):161S-170S.
143. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm. 1988;74(3):199-205.
144. Cassarino DS, Fall CP, Swerdlow RH, et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson’s disease. Biochim Biophys Acta. 1997;1362(1):77-86.
145. Di Maio R, Barrett PJ, Hoffman EK, et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci Transl Med. 2016;8(342):342ra78.
146. Anandhan A, Rodriguez-rocha H, Bohovych I, et al. Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. Neurobiol Dis. 2015;81:76-92.
147. Carboni E, Lingor P. Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson’s disease. Metallomics. 2015;7(3):395-404.
148. Hastings TG. The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease. J Bioenerg Biomembr. 2009;41(6):469-472.
149. Leong SL, Cappai R, Barnham KJ, Pham CL. Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem Res. 2009;34(10):1838-1846.
150. Cristóvão AC, Guhathakurta S, Bok E, et al. NADPH oxidase 1 mediates α-synucleinopathy in Parkinson’s disease. J Neurosci. 2012;32(42):14465-14477.
151. Schildknecht S, Gerding HR, Karreman C, et al. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem. 2013;125(4):491-511.